New advances in the treatment of neonatal diabetes mellitus with sulfonylureas
- VernacularTitle:磺酰脲类药物治疗新生儿糖尿病的研究新进展
- Author:
Xiaoyan HU
1
;
Jinbo XIANG
1
;
Xiaoxia ZHU
1
;
Zheng LI
1
;
Tingting CAO
1
;
Ting DING
1
;
Ziran XU
1
;
Jingbo LI
1
;
Youjun YANG
1
Author Information
1. Dept. of Pediatrics，the Affiliated Renhe Hospital of China Three Gorges University，Hubei Yichang 443001，China
- Publication Type:Journal Article
- Keywords:
neonatal diabetes mellitus;
sulfonylureas;
glibenclamide;
gene mutation;
KCNJ11 gene;
ABCC8 gene
- From:
China Pharmacy
2026;37(9):1236-1240
- CountryChina
- Language:Chinese
-
Abstract:
Neonatal diabetes mellitus （NDM） is a rare monogenic disorder primarily caused by insufficient insulin secretion resulting from mutations in the KCNJ11 and ABCC8 genes. Sulfonylureas， represented by glibenclamide， have become the standard therapy for this type of NDM by precisely closing the mutated ATP-sensitive potassium channels in pancreatic β cells， thereby restoring insulin secretion. Clinical studies confirm that sulfonylureas enable over 90% of patients to successfully transition from insulin to oral treatment， achieving long-term stable glycemic control and improving neurological outcomes to a certain extent. In terms of safety， severe hypoglycemia induced by sulfonylureas is relatively rare and gastrointestinal reactions are mild； moreover， sulfonylureas show good long-term tolerability， and have no adverse effects on child growth and development. In the future， by further refining the full-chain management pathway of “rapid genetic diagnosis-early intervention-specialized dosage forms-long-term follow-up”， the clinical application of sulfonylureas is expected to provide NDM patients with an optimized treatment regimen and maximize their health benefits.
